A systems biology approach to programmed cell death in prostate cancer: Biomarker discovery and therapeutic potential of DL-PDMP.
2/5 보강
TL;DR
It is suggested that targeting PCD-associated biomarkers is a promising strategy for prostate cancer treatment, making DL-PDMP a strong candidate for further preclinical studies.
OpenAlex 토픽 ·
Ferroptosis and cancer prognosis
Prostate Cancer Treatment and Research
Cancer, Stress, Anesthesia, and Immune Response
It is suggested that targeting PCD-associated biomarkers is a promising strategy for prostate cancer treatment, making DL-PDMP a strong candidate for further preclinical studies.
APA
Elif Kubat Oktem, Muhammed Yasar Bener, Ummuhan Demir (2026). A systems biology approach to programmed cell death in prostate cancer: Biomarker discovery and therapeutic potential of DL-PDMP.. Computational biology and chemistry, 122, 108912. https://doi.org/10.1016/j.compbiolchem.2026.108912
MLA
Elif Kubat Oktem, et al.. "A systems biology approach to programmed cell death in prostate cancer: Biomarker discovery and therapeutic potential of DL-PDMP.." Computational biology and chemistry, vol. 122, 2026, pp. 108912.
PMID
41576692 ↗
Abstract 한글 요약
Prostatic adenocarcinoma (PRAD) is among the most common malignancies in men and is characterized by considerable genetic and epigenetic heterogeneity. Despite advances in diagnosis and treatment, options for advanced and refractory prostate cancer remain limited, which adversely affects patient prognosis. This project aims to identify diagnostic and prognostic biomarkers associated with programmed cell death (PCD) mechanisms in prostate cancer and to reposition existing drugs that target these biomarkers. Using RNA-seq and clinical data from The Cancer Genome Atlas (TCGA), differential gene expression, ROC curve, and survival analyses identified six candidate biomarkers with strong diagnostic and prognostic significance. Three small molecules - DL-PDMP, clobetasol propionate, and metoclopramide hydrochloride - capable of reversing gene expression profiles were selected for in vitro assays in a drug repositioning analysis conducted using the L1000CDS2 platform. Among these, DL-PDMP was prioritized because of its low IC value and low toxicity to normal prostate epithelial cells. Furthermore, DL-PDMP has been shown to induce apoptosis and suppress colony formation. These findings suggest that targeting PCD-associated biomarkers is a promising strategy for prostate cancer treatment, making DL-PDMP a strong candidate for further preclinical studies.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.